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Abstract. Targeting peroxisome proliferator-activated receptor 𝛾 (PPAR𝛾) by synthetic
compounds has been shown to elicit insulin sensitising properties in type 2 diabetics. Treatment
with a class of these compounds, the thiazolidinediones (TZDs), has shown adverse side
effects such as weight gain, fluid retention, and congestive heart failure. This is due to their
full agonist properties on the receptor, where a number of genes are upregulated beyond
normal physiological levels. Lessened transactivation of PPAR𝛾 by partial agonists has proved
beneficial in terms of reducing side effects, while still maintaining insulin sensitising properties.
However, some partial agonists have been associated with unfavourable pharmacokinetic
profiles due to their acidic moieties, often causing partitioning to the liver. Here we present
SR1988, a new partial agonist with favourable non-acid chemical properties. We used a
combination of X-ray crystallography and hydrogen/deuterium exchange (HDX) to elucidate
the structural basis for reduced activation of PPAR𝛾 by SR1988. This structural analysis reveals
a mechanism that decreases stabilisation of the AF2 coactivator binding surface by the ligand.
Keywords: PPAR𝛾 , partial agonist, nuclear receptor, type 2 diabetes, HDX
1. Introduction
PPAR𝛾 is a ligand-modulated transcription factor belonging to the nuclear receptor superfamily.
It forms a heterodimer with retinoid X receptor 𝛼 (RXR𝛼) to play key roles in metabolism and
the maintenance of glucose homeostasis through modulating numerous target genes [1, 2]. The
receptor is a well-established target for treatments of type 2 diabetes (T2DM) for its roles in
modulating insulin sensitivity in peripheral tissues.
Sequence analysis and crystallographic studies reveal that PPAR𝛾 displays the conserved
nuclear receptor domain architecture, comprising of the activation function 1 domain essential
for ligand-independent coregulator binding, a DNA binding domain (DBD), a hinge region,
and a ligand binding domain (LBD). The LBD binds a number of endogenous ligands, as well
as facilitating dimerisation with RXR𝛼, and contains a regulatory activation function 2 (AF2)
regionwhich binds coregulators in a ligand-dependantmanner [3]. Crystal structures of the LBD
show that the domain contains 13 𝛼-helices (H1-12 and 2’) and a small 𝛽-sheet, conforming to
the canonical nuclear receptor LBD tertiary fold. The ligand binding pocket within the LBD is
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lined with hydrophobic residues, enabling binding of predominantly hydrophobic endogenous
ligands.
The thiazolidinediones (TZDs) are a class of full agonist modulators of PPAR𝛾 , which
include rosiglitazone (Avandia, GSK) and pioglitazone (Actos, Takeda). Crystal structures of
rosiglitazone-bound PPAR𝛾 LBD have shown that the thiazolidinedione head group forms
robust stabilising interactions with the activation helix (H12) to enable coactivator binding and
initiation of target gene expression [3-7]. Rosiglitazone and pioglitazone have previously been
prescribed to treat type 2 diabetes, but their use has been hampered by harmful side effects
associated with supraphysiological activation of PPAR𝛾 target genes. The upregulation of
these genes leads to weight gain, loss of bone density, renal fluid retention and plasma volume
expansion, oedema, and heart failure. These side effects have led to the clinical use of TZDs
being restricted in most cases and highlights the necessity for improved antidiabetic agents
targeting PPAR𝛾 .
In light of the issues with TZDs as antidiabetics, research has focused on developing ligands
of PPAR𝛾 with reduced activation of the receptor which show a more favourable side effect
profile due to a reduced expression of PPAR𝛾 target genes. Although these ligands show low
activation of the receptor, they still exhibit robust antidiabetic effects comparable to TZDs. It
has been established that the insulin sensitising properties of ligands of PPAR𝛾 are attributed
to their ability to block phosphorylation of PPAR𝛾 at Ser273 by extracellular signal-regulated
kinases (e.g., CDK5, ERK) [8, 9]. The blocking of phosphorylation is independent of the level
of transactivation of the receptor induced by the ligand. It is paramount that T2DM research
focusses on ligands of PPAR𝛾 that have minimal activation of the receptor, such as partial
agonists and antagonists, while still maintaining phosphorylation-blocking abilities.
A number of partial agonists have been investigated for their suitability as antidiabetic agents
[10-15]. This approach is promising, with studies showing that the insulin-sensitising prop-
erties remain in these compounds with reduced transactivation of PPAR𝛾 . An example of a
well-studied partial agonist of PPAR𝛾 is INT131, which shows effective blocking of Ser273
phosphorylation in vitro, indicative of its effectiveness as an antidiabetic agent, and showed
lowered side effects as a result of limited transactivation of PPAR𝛾 [12].
The array of endogenous and synthetic ligands capable of binding in the ligand binding pocket
of PPAR𝛾 have a diverse range of chemical properties [16]. These include sulphonamides,
indoles, acids, benzimidazoles, thiazolidinediones, and cercosporamide derivatives [2]. The
majority of these contain acid groups for stabilising helix 12 or the 𝛽-sheet of the LBD to
mediate high affinity binding to the receptor [13]. However, acid moieties are disadvantageous
in that they exhibit unfavourable pharmacokinetic profiles, with the compounds partitioning
to the liver in vivo [14]. This could limit their effectiveness at their intended site of action; the
peripheral tissues where the response to insulin occurs. Developing a non-acid ligand of PPAR𝛾
with limited transactivation of the receptor will be ideal for an effective antidiabetic agent with
favourable pharmacokinetics and side effect profile.
We have previously reported our findings on a ligand of PPAR𝛾 which fits these criteria,
SR2067, a highly potent non-acid partial agonist which displayed reduced transactivation of the
receptor in a GAL4 transactivation assay [13]. Here we present an analogue of SR2067: SR1988,
a non-acid partial agonist of PPAR𝛾 . A transactivation assay was performed to determine the
transcriptional potency of SR1988, a crystal structure of the ligand in complex with the PPAR𝛾
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LBD has been solved, and HDX was performed to further elucidate its mechanism of action
through protein conformational dynamics.
2. Materials andMethods
2.1. Synthesis of SR1988
1-(2,4-difluorobenzyl)-2,3-dimethyl-N-(1-phenylpropyl)-1H-indole-5-carboxamide.
Step 1: NaH (1.1 equiv) was added to a solution of ethyl 2,3-dimethy 1-1 H-indole-5-carboxylate
in DMF at room temperature. After 30 min, 2,4-difluorobenzyl bromide (1.1 equiv) was added
to the reaction mixture and stirred for 1 h. After the reaction was completed, the solvent was
removed in vacuo to obtain a crude residue which was purified by flash chromatography on
silica gel (ethyl acetate/hexanes 10–100%) to obtain ethyl 1-(2,4-difluorobenzyl)-2,3-dimethyl-
1H-indole-5-carboxylate. LC-MS 344 (M+H).
Step 2: A mixture of above compound and NaOH (10 equiv) in EtOH was refluxed at 100∘
C. for 2 h. The reaction mixture was cooled to room temperature, then acidified to pH-4 with
saturated citric acid. The mixture was evaporated in vacuo to obtain the crude product, which
was precipitated in water and filtered to obtain 1-(2,4-difluorobenzyl)-2,3-dimethyl-1H-indole-
5-carboxylic acid which was used without further purification. LC-MS 316 (M+H).
Step 3: To a mixture of this acid in DMF was added DIPEA (1.3 equiv) and HATU (1.2 equiv).
The mixture was stirred for 5 min, and then 𝛼-ethylbenzylamine (1.1 equiv) was added. The
reaction mixture was stirred at room temperature for 1 h. After the reaction was completed, the
solvent was removed in vacuo to obtain the crude which was purified by flash chromatography
on silica gel (ethyl acetate/hexanes 10–100%) to obtain 1-(2,4-difluorobenzyl)-2,3-dimethyl-N-
(1-phenylpropyl)-1H-indole-5-carboxamide as a colourless solid. LC-MS 433 (M+H).
2.2. Synthesis of SR2067
1-(naphthalen-1-ylsulfonyl)-N-(1-phenylpropyl)-1H-indole-5-carboxamide.
Step 1: To a mixture of 1H-indole-5-carboxylic acid in DMF was added DIPEA (1.3 equiv) and
HATU (1.2 equiv). The mixture was stirred for 5 min, and then 𝛼-ethylbenzylamine (1.1 equiv)
was added. The reaction mixture was stirred at room temperature for 1 h. After the reaction was
completed, the solvent was removed in vacuo to obtain the crude which was purified by flash
chromatography on silica gel (ethyl acetate/hexanes 10–100%) to obtain N-(1-phenylpropyl)-
1H-indole-5-carboxamide as a colourless solid.
Step 2: 1-naphthylsulfonyl chloride (1.1 equiv) and benzyltriethylammonium chloride (0.5
equiv) were added to a solution of N-(1-phenylpropyl)-lH-indole-5-carboxamide in CH2Cl2 and
KOH (1.3 equiv) at room temperature. After the reaction was judged complete by analytical
reverse-phase HPLC analysis, the solvent was evaporated and the crude residue was purified
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by silica gel column chromatography (ethyl acetate/hexanes 10–100%) to afford 1-(naphthalen-
1-ylsulfonyl)-N-(1-phenylpropyl)-1H-indole-5-carboxamide as a colourless solid. LC-MS 469
(M+H).
2.3. Cell-based transactivation assay
HEK293T cells (ATCC; cat# CRL-3216) were cotransfected in batch by adding 4.5 𝜇g human
GAL4-PPAR𝛾-Hinge-LBD,with 4.5𝜇g 5XmultimerizedUAS-luciferase reporter and 27𝜇LX-
treme Gene 9 transfection reagent in serum-free Opti-mem reduced serummedia (Gibco). After
18-h incubation at 37 ∘C in a 5% CO2 incubator, transfected cells were plated in quadruplicate
in white 384-well plates (Perkin Elmer) at a density of 10,000 cells per well. After replating,
cells were treated with either DMSO only or the indicated compounds in increasing doses from
2 pM–10 𝜇M. After 18-h incubation, treated cells were developed with Brite Lite Plus (Perkin
Elmer) and read in 384-well Luminescence Perkin Elmer EnVision Multilabel plate reader.
Graphs were plotted as fold change of treated cells over DMSO-treated control cells.
2.4. Protein purification, complex formation and crystallisation
6xHis-hPPAR𝛾 LBD (res 205-477) was expressed using a pET-11a expression vector in
BL21DE3 E. coli cells. Expression was induced at mid-log phase using 0.5mM IPTG at 16∘C
overnight. Cells were harvested and lysed using a cell disruptor in 20mM Tris 8.0, 0.5M NaCl,
10mM imidazole, and 2mM BME. Protein was purified using 5mL Ni2+ IMAC FF Crude
Column (GE Healthcare), followed by size exclusion chromatography using a HiPrep 26/60
Sephacryl S 300 HR column. The protein was concentrated to 10mg/mL using a centrifugal
concentrator with a 10,000 molecular weight cut-off. Crystals were formed at 16∘C using the
hanging drop method. The well consisted of 1.2M sodium citrate and 0.1M Tris 8.0. The
hanging drop was formed by mixing 1𝜇L of well solution with 1𝜇L of apo protein solution.
2.5. Structure determination
Apo crystals of PPAR𝛾 were soaked with SR1988. SR1988 was soaked at a concentration of
2.5mM for 3 weeks at 16 𝑜C. 15% ethylene glycol was used as a cryoprotectant. Diffraction data
were collected at the MX1 beamline at the Australian Synchrotron. 360∘ of diffraction data at 1
degree rotations were collected for the PPAR𝛾 + SR1988 crystal at one second exposure times
with 85% attenuation of the beam. Processing of the data was performed using iMosflm (CCP4),
which processed reflections from 58-2.4Åwith space group C 1 2 1. Molecular replacement was
performed using PhaserMR with PDB 4R06 (with water molecules and ligands removed) as the
search model. Eight rounds of refinement in Phenix.refine showed that there was significant
density for SR1988 in the binding pocket of chain A. Manual rebuilding in Coot followed




2.6. Hydrogen/deuterium exchange (HDX) detected by
mass spectrometry (MS)
Differential HDX-MS experiments were conducted as previously described with some modifi-
cations [17].
2.6.1. Peptide identification
Peptides were identified using tandem MS (MS/MS) with an Orbitrap mass spectrometer
(Q Exactive, Thermo Fisher). Product ion spectra were acquired in data-dependent mode
with the top five most abundant ions selected for the product ion analysis per scan event.
The MS/MS data files were submitted to Mascot (Matrix Science) for peptide identification.
Peptides included in the HDX analysis peptide set had aMASCOT score greater than 20 and the
MS/MS spectra were verified by manual inspection. The MASCOT search was repeated against
a decoy (reverse) sequence and ambiguous identifications were ruled out and not included in
the HDX peptide set.
2.6.2. HDX-MS analysis
Protein (10 𝜇M)was incubated with the respective ligands at a 1:10 protein-to-ligandmolar ratio
for 1 h at room temperature. Next, 5 𝜇l of sample was diluted into 20 𝜇l D2Obuffer (20mMTris-
HCl, pH 7.4; 150 mM NaCl; 2 mM DTT) and incubated for various time points (0, 10, 60, 300,
and 900 s) at 4∘C. The deuterium exchange was then slowed bymixing with 25 𝜇l of cold (4∘C) 3
M urea and 1% trifluoroacetic acid. Quenched samples were immediately injected into the HDX
platform. Upon injection, samples were passed through an immobilized pepsin column (2mm ×
2cm) at 200 𝜇l min−1 and the digested peptides were captured on a 2mm × 1cm C8 trap column
(Agilent) and desalted. Peptides were separated across a 2.1mm × 5cm C18 column (1.9 𝜇l
Hypersil Gold, Thermo Fisher) with a linear gradient of 4% - 40% CH3CN and 0.3% formic
acid, over 5 min. Sample handling, protein digestion and peptide separation were conducted
at 4∘C.Mass spectrometric data were acquired using anOrbitrapmass spectrometer (Q Exactive,
Thermo Fisher). HDX analyses were performed in triplicate, with single preparations of each
protein ligand complex. The intensity weighted mean m/z centroid value of each peptide enve-
lope was calculated and subsequently converted into a percentage of deuterium incorporation.
This was accomplished by determining the observed averages of the undeuterated and fully
deuterated spectra and using the conventional formula described elsewhere [18]. Statistical
significance for the differential HDX data is determined by an unpaired t-test for each time
point, a procedure that is integrated into the HDX Workbench software [19]. Corrections for
back-exchange were made on the basis of an estimated 70% deuterium recovery, and accounting
for the known 80% deuterium content of the deuterium exchange buffer.
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Figure 1: SR1988 is a non-acid partial agonist of PPAR𝛾. (A) Chemical structure of SR2067 and its analogue
SR1988. (B) Transactivation data for SR1988. The transcriptional activity of SR1988 on PPAR𝛾 was determined
using a GAL4 transactivation assay. Data points were repeated in triplicate. Maximum transactivation values are
normalised to Rosiglitazone.
3. Results and Discussion
3.1. Design and transcriptional activity of non-acid PPARγ ligand
SR1988
The pharmacokinetic liabilities of PPAR𝛾 ligands with acid moieties has prompted the investi-
gation of ligands designed to bind PPAR𝛾 with high affinity without acidic properties. Our pre-
viously reported non-acid partial agonist SR2067 displayed reduced transactivation of PPAR𝛾
while still maintaining high potency binding to the receptor [13]. We sought to probe the effects
of modifying SR2067 from the site of the 1-(methylsulphonyl)naphthalene region of the ligand
by generating SR1988, which still maintained the desired non-acid characteristics of SR2067.
SR1988 contains a central 2, 3-dimethylindolemoiety flanked by a 2, 4-difluorobenzene and a
hydrophobic phenylpropyl group with a terminal ethyl moiety joined by an amide linker (Figure
1A). The presence of key hydrophobic moieties within the ligand is vital for binding to the
hydrophobic ligand binding pocket of PPAR𝛾 .
Non-acid agonists of PPAR𝛾 are advantageous in that they have ideal pharmacokinetic
attributes in terms of preventing partitioning to the liver, and can carry out their insulin-
sensitising properties in the required organs [13]. It is for this reason the non-acid properties
of SR1988 makes it an improvement on previous partial agonists, while still retaining the
advantages attributed to partial agonists as antidiabetic agents.
We have previously reported that SR2067 displays a maximal transactivation approximately
55-fold higher than DMSO, 60% relative to the maximal transactivation of rosiglitazone [13].
We performed a cell-based transactivation assay in order to compare the level of PPAR𝛾 acti-
vation exhibited by SR1988 (Figure 1B). This revealed a maximal transactivation by SR1988
approximately 50-fold higher thanDMSO, 45% relative to themaximal transactivation exhibited
by rosiglitazone. This is typical of partial agonists and is a desired characteristic in ligands
of PPAR𝛾 for the treatment of type 2 diabetes. The low activation of the receptor by ligands
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means that PPAR𝛾 target genes will not be expressed at a supraphysiological level, indicative
of reduced side effects in comparison to TZDs.
The concentration of SR1988 that gave half maximal transactivation (EC50) was 123nM, a
lower concentration than the EC50 of rosiglitazone, which gave half maximal transactivation at
494nM. This indicates that SR1988 is more potent than rosiglitazone in binding, and represents
a major improvement on rosiglitazone in addition to the desired decrease in maximal PPAR𝛾
activation. SR2067 displayed an EC50 value of 16nM, approximately an 8-fold lower EC50
than SR1988, suggesting that SR2067 is somewhat a more highly potent ligand of PPAR𝛾 than
SR1988. Despite this, both EC50 values are suitable in terms of clinical applications as they are
both in the low nanomolar range. In addition, SR1988 shows an advantage over SR2067 in terms
of its lower relative transactivation of PPAR𝛾 , where SR1988 exhibited a 45% transactivation
of PPAR𝛾 , compared to 60% shown by SR2067. This lower activation will likely correspond
to a more favourable side effect profile, inarguably a more important characteristic of a drug
candidate.
3.2. X-ray crystal structure of PPARγ LBD bound to SR1988
We obtained a crystal structure of SR1988-bound PPAR𝛾 LBD and solved it to 2.4Å (Figure
2A), with data refinement statistics in Table 1. The asymmetric unit of the crystal was comprised
of two LBD subunits with homodimeric architecture. The protein main chain conformed to
the canonical homodimeric PPAR𝛾 LBD fold, with little variation in comparison to previously
solved structures (RMSD of 0.58Å across 244 C𝛼 atoms compared with rosiglitazone-bound
PPAR𝛾 LBD, PDB:2PRG, and a 0.44Å RMSD over 251 C𝛼 atoms compared with apo PPAR𝛾
LBD, PDB:1PRG). The SR1988 ligand was modelled into one chain of the homodimer, with a
Polder omit map [20] displaying reduced model bias and exclusion of solvent molecules shown
in Figure 1 in Supplementary Material available online at http://www.agialpress.com/journals/
nurr/2018/101350/. SR1988was bound in the ligand binding pocket of the LBD in a very similar
way to a number of PPAR𝛾 agonists, wrapping around H3 to make contacts with residues of
H12 as well as the 𝛽-sheet. The central amide of the ligand forms two hydrogen bonds with
the receptor (Figure 2B); the carbonyl accepting a hydrogen from Tyr327 of helix 5 over a
distance of 3.3Å, and the amine donating a hydrogen to Ser289 of helix 3 in a 2.4Å hydrogen
bond. In addition, hydrophobic interactions are made between the ligand and residues lining the
binding pocket. The indole moiety of the ligand makes hydrophobic interactions with Cys285
(H3), Ile326 (H5) and Leu330 (H5), and the 2, 4-difluorobenzene interacts with Cys285 (H3),
Arg288 (H3), and Ile341 (𝛽-sheet). The phenylpropyl moiety forms hydrophobic interactions
with Leu453 (H11) and Leu469 (H12).
This combination of hydrogen bonds and hydrophobic interactions made between SR1988
and PPAR𝛾 are high affinity and probably entropically favourable, giving SR1988 the high
potency revealed in the transactivation assay. This is key for the development of insulin-
sensitising agents, as compounds that bind tightly to PPAR𝛾 but have only minor transactivation
of the receptor are ideal for the treatment of T2DM.
Comparison of SR1988 and SR2067 binding modes reveal almost complete similarity in the
specific interactions formed with residues of the binding pocket (Figure 2 in Supplementary
Material available online at http://www.agialpress.com/journals/nurr/2018/101350/), with only
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Table 1: Crystallographic data statistics.
PDB accession code 6D3E
Space group C 1 2 1
Cell dimensions
a, b, c (Å) 93.04, 62.51, 118.65
𝛼, 𝛽, 𝛾 (∘) 90, 102.32, 90
X-ray source Australian Synchrotron MX1
Wavelength (Å) 0.9537
Resolution range (Å) 58.0-2.40 (2.49-2.40)
Rmerge (%)𝑎 0.12 (1.18)
Rpim (%) 0.075 (0.794)
Observations 155718 (13591)
Unique reflections 26013 (2563)














Bond length (Å) 0.002
Bond angle (deg) 0.42
B-factors (Å2)
Overall 63.7
Average protein atoms 63.5
Average ligand atoms 105.5
Average solvent 59.4
Ramachandran statistics
Most favoured regions (%) 96.71
Allowed regions (%) 3.10
Disallowed regions (%) 0.19
Values in parentheses correspond to the last shell.
𝑎Rmerge = Σ |I − < I >| / Σ I.
𝑏Rwork = Σ |F𝑜− F𝑐 | / Σ |F𝑜| for all data excluding data used to calculate Rfree.
𝑐Rfree = Σ |F𝑜 − F𝑐 | / Σ |F𝑜|, for all data.
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Figure 2:Crystal structureofPPAR𝛾 LBDboundtoSR1988. (A) Ribbons representation of PPAR𝛾 LBD (green)
bound to SR1988 (purple sticks). Only chain A is shown of the homodimeric asymmetric unit of the crystal. (B)
Interactions made between SR1988 and residues lining the ligand binding pocket. Contributing side chains are shown
as green sticks, with residue identities labelled.
minor differences in hydrophobic interacting residues. The central amide forms the same hydro-
gen bonds as seen for SR1988, across 2.6Å for both hydrogen bonds with Tyr327 and Ser289.
The unmodified phenylpropyl moiety of the two analogues are positioned in the same space
within the ligand binding pocket, forming hydrophobic interactions with Leu453 (H11) and
Leu469 (H12). The differing chemical structures of the ligands resulted in slight differences in
their EC50 values, which can be attributed to minor variances in their ligand binding modes.
The sulphonyl linker of SR2067 does not appear to provide an advantage in terms of favourable
ligand binding compared with the carbon linker of SR1988 in the same location, as both linkers
enable the ligand to orient in a way that regions of the compounds either side of the linker can
form favourable interactions with the receptor. The naphthalene moiety of SR2067 occupies
the same region of space in the binding pocket of PPAR𝛾 , and interacts with the same residues
as the 2, 4-difluorobenzene of SR1988. The higher binding potency of SR2067 could perhaps
be accounted to the higher hydrophobicity of naphthalene compared with 2, 4-difluorobenzene,
which would increase the likelihood of binding to PPAR𝛾 and interacting with the hydrophobic
pocket of the receptor. These discreet differences in the specific interactions made with the
receptor by ligands of differing chemical structures highlight the importance of optimising
ligands at the chemical level to enhance their potency and minimise their transactivation of
PPAR𝛾 .
3.3. Conformational dynamics of the SR1988-PPARγ complex as
measured by HDX
In order to determine the protein dynamic stabilisation profile of the ligand-bound receptor, we
performed hydrogen/deuterium exchange (HDX) on PPAR𝛾 LBD in the presence of SR1988 as
well as rosiglitazone (Figure 3), with HDX behaviour and peptide identities shown in Table I
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Figure 3: SR1988 displays a receptor stabilisation profile typical of PPAR𝛾 partial agonists. HDX data
for the corresponding peptides are plotted over the structures of PPAR𝛾 LBD bound to rosiglitazone (PDB 2PRG)
and SR1988 (PDB: 6D3E). Percentage reduction (average of all replicates and all time points) in HDX relative to
apo receptor is coloured according to the key. Residues are coloured to correspond to the average percent change in
deuteration between apo and SR1988 or rosiglitazone bound PPAR𝛾 LBD.
in Supplementary Material available online at http://www.agialpress.com/journals/nurr/2018/
101350/. SR1988 displayed a HDX pattern characteristic of partial agonists. Moderate sta-
bilisation of H12 was observed in comparison to rosiglitazone-bound PPAR𝛾 LBD, where
“stabilisation” refers to decreased molecular motion of H12 in its orientation relative to the
remainder of the LBD. H12 of nuclear receptor LBDs has been considered a “molecular switch”
for graded nuclear receptor activation, where the degree of stabilisation of H12 governs the
ability for coregulators to bind, and hence determines the degree of transcriptional output exhib-
ited by the receptor [21, 22]. Previous structural studies have shown that rosiglitazone sta-
bilises H12 through a network of hydrogen bonds mediated by the thiazolidinedione head group
of rosiglitazone, which enables robust recruitment of coactivators through stabilisation of the
ligand-dependant AF2 coactivator binding surface [4]. This hydrogen bond network is lacking
in SR1988, as there is a phenylpropyl group occupying this space near H12 instead of a thiazo-
lidinedione, placing hydrophobic moieties in the pocket near the AF2. The hydrophobic moi-
eties are not as conformationally constraining as the extensive hydrogen bond network formed
between rosiglitazone and H12, which leads to a reduced stabilisation of H12 by SR1988. A
decreased stabilisation of H12 suggests a lessened propensity to recruit coactivators and so
will exhibit a reduced transcriptional activation of PPAR𝛾 , indicating a key contributor to the
mechanism of partial agonism by SR1988.
In addition, it has been shown that a graded transcriptional output of PPAR𝛾 can be deter-
mined by factors extending beyond the degree of H12 stabilisation [15]. Partial agonists gener-
ally stabilise regions of H3 and the 𝛽-sheet of the LBD to carry out their moderate transcriptional
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activation [9, 15]. HDX shows that SR1988 stabilised H3 to a higher degree than rosiglitazone.
This can be attributed to the hydrogen bond with Ser289 of helix 3, as well as the stabilising
hydrophobic interactions with Cys285 and Arg288 identified by the crystal structure. These
interactions formed between SR1988 and helix 3 of PPAR𝛾 decrease the conformationally
dynamic nature of the apo LBD, likely serving to allow decreased coactivator binding, giving
SR1988 its partial agonist characteristics. Aminor increase in 𝛽-sheet stabilisationwas observed
by HDX for SR1988 compared with rosiglitazone and DMSO controls, which has also been
shown to contribute to partial agonist characteristics.
Differences in maximal transactivation efficacy of SR1988 (45%) and SR2067 (60%) can be
attributed in part to differential stabilisation of regions of the LBD of PPAR𝛾 . SR2067 displayed
stabilising interactions with the 𝛽-sheet and H3 to give partial agonist properties [13]. This is
similar to SR1988, although a direct comparison of the stabilisation of PPAR𝛾 by SR1988 or
SR2067 using HDX can provide an explanation for the differences in PPAR𝛾 transactivation
exhibited by SR1988 and SR2067.
4. Conclusion
In summary, we have used a combination of X-ray crystallography and HDX to define the
mechanism of PPAR𝛾 partial agonism by SR1988. A reduced stabilisation of H12 as well
as increased stabilisation of H3 and the 𝛽-sheet in comparison to rosiglitazone account for
moderate, partial agonist like transactivation of PPAR𝛾 by SR1988. Our study demonstrates
that non-acid ligands of PPAR𝛾 still exhibit high affinity binding to the receptor, despite their
lack of acidic moieties to stabilise regions of the LBD. These findings are applicable to the future
development of insulin sensitising agents, particularly for its low transactivation as well as non-
acid characteristics, giving it more ideal pharmacokinetic properties and likely a favourable side
effect profile.
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